Royalty Pharma

At a glance

Royalty Pharma reported 2025 revenue of $2.38B, up 5.1% from $2.26B in 2024. Over 4 years since 2021 ($2.29B), that is growth of about 1% a year. Operating margin was 65.6%, up from 62.5% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 5 insiders reported 0 open-market purchases and 38 sales ($92.8M). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $10.4M by EVP & CFO Terrance P. Coyne on Feb 4, 2026.

Royalty Pharma filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), regulation fd disclosure (2), shareholder vote results (1) and material agreement (1). The latest officer or director change was reported on Dec 22, 2025. It reported a material agreement or a completed acquisition or disposal 1 time.

3 of the 20 investors tracked here held Royalty Pharma at the last quarter end, worth $160.5M combined. It is the largest weight for Renaissance Technologies (0.1% of its portfolio), followed by Bridgewater Associates (0.1%). New this quarter: Bridgewater Associates. Added: Renaissance Technologies. Reduced: National Pension Service (Korea).

Annual results

Fiscal year ends Dec 31 · incorporated in X0

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.